ADAPTIVE BIOTECHNOLOGIES CORPORATION Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $5.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $5.80M, a 82.48% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $33.10M, a 40.68% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $55.80M, a 12.50% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $49.60M, a 50.15% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $5.80M 10-K · filed 2026-02-26 |
| 2024-12-31 | $33.10M 10-K · filed 2026-02-26 |
| 2023-12-31 | $55.80M 10-K · filed 2025-03-03 |
| 2022-12-31 | $49.60M 10-K · filed 2024-02-29 |
| 2021-12-31 | $99.50M 10-K · filed 2023-02-14 |
| 2020-12-31 | $96.60M 10-K · filed 2022-02-15 |
| 2019-12-31 | $30.20M 10-K · filed 2021-02-24 |
| 2018-12-31 | $14.00M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |